Dcf Advisers, LLC Immuno Gen, Inc. Transaction History

Dcf Advisers, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$12.46 - $29.95 $14,329 - $34,442	1,150 Added 8.95%	14,000 $415,000
Q3 2023 Nov 13, 2023	BUY	$14.09 - $19.87 $35,225 - $49,675	2,500 Added 24.15%	12,850 $203,000
Q2 2023 Aug 09, 2023	BUY	$3.75 - $20.05 $38,812 - $207,517	10,350 New	10,350 $195,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Dcf Advisers, LLC, based on Form 13F filings with the SEC.

Stay updated on Dcf Advisers, LLC with notifications on news.